Literature DB >> 24480483

X-linked adrenoleukodystrophy in women: a cross-sectional cohort study.

Marc Engelen1, Mathieu Barbier, Inge M E Dijkstra, Remmelt Schür, Rob M A de Bie, Camiel Verhamme, Marcel G W Dijkgraaf, Patrick A Aubourg, Ronald J A Wanders, Bjorn M van Geel, Marianne de Visser, Bwee T Poll-The, Stephan Kemp.   

Abstract

X-linked adrenoleukodystrophy is the most common peroxisomal disorder. The disease is caused by mutations in the ABCD1 gene that encodes the peroxisomal transporter of very long-chain fatty acids. A defect in the ABCD1 protein results in elevated levels of very long-chain fatty acids in plasma and tissues. The clinical spectrum in males with X-linked adrenoleukodystrophy has been well described and ranges from isolated adrenocortical insufficiency and slowly progressive myelopathy to devastating cerebral demyelination. As in many X-linked diseases, it was assumed that female carriers remain asymptomatic and only a few studies addressed the phenotype of X-linked adrenoleukodystrophy carriers. These studies, however, provided no information on the prevalence of neurological symptoms in the entire population of X-linked adrenoleukodystrophy carriers, since data were acquired in small groups and may be biased towards women with symptoms. Our primary goal was to investigate the symptoms and their frequency in X-linked adrenoleukodystrophy carriers. The secondary goal was to determine if the X-inactivation pattern of the ABCD1 gene was associated with symptomatic status. We included 46 X-linked adrenoleukodystrophy carriers in a prospective cross-sectional cohort study. Our data show that X-linked adrenoleukodystrophy carriers develop signs and symptoms of myelopathy (29/46, 63%) and/or peripheral neuropathy (26/46, 57%). Especially striking was the occurrence of faecal incontinence (13/46, 28%). The frequency of symptomatic women increased sharply with age (from 18% in women <40 years to 88% in women >60 years of age). Virtually all (44/45, 98%) X-linked adrenoleukodystrophy carriers had increased very long-chain fatty acids in plasma and/or fibroblasts, and/or decreased very long-chain fatty acids beta-oxidation in fibroblasts. We did not find an association between the X-inactivation pattern and symptomatic status. We conclude that X-linked adrenoleukodystrophy carriers develop an adrenomyeloneuropathy-like phenotype and there is a strong association between symptomatic status and age. X-linked adrenoleukodystrophy should be considered in the differential diagnosis in women with chronic myelopathy and/or peripheral neuropathy (especially with early faecal incontinence). ABCD1 mutation analysis deserves a place in diagnostic protocols for chronic non-compressive myelopathy.

Entities:  

Keywords:  X-inactivation; adrenoleukodystrophy; carriers; faecal incontinence; myelopathy

Mesh:

Substances:

Year:  2014        PMID: 24480483     DOI: 10.1093/brain/awt361

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  65 in total

Review 1.  An overview of inborn errors of metabolism manifesting with primary adrenal insufficiency.

Authors:  Fady Hannah-Shmouni; Constantine A Stratakis
Journal:  Rev Endocr Metab Disord       Date:  2018-03       Impact factor: 6.514

Review 2.  The Changing Face of Adrenoleukodystrophy.

Authors:  Jia Zhu; Florian Eichler; Alessandra Biffi; Christine N Duncan; David A Williams; Joseph A Majzoub
Journal:  Endocr Rev       Date:  2020-08-01       Impact factor: 19.871

Review 3.  Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis.

Authors:  James D Weisfeld-Adams; Ilana B Katz Sand; Justin M Honce; Fred D Lublin
Journal:  Brain       Date:  2015-01-29       Impact factor: 13.501

4.  Activation of sirtuin 1 as therapy for the peroxisomal disease adrenoleukodystrophy.

Authors:  L Morató; M Ruiz; J Boada; N Y Calingasan; J Galino; C Guilera; M Jové; A Naudí; I Ferrer; R Pamplona; M Serrano; M Portero-Otín; M F Beal; S Fourcade; A Pujol
Journal:  Cell Death Differ       Date:  2015-03-27       Impact factor: 15.828

5.  When multiple sclerosis and X-linked adrenoleukodystrophy are tangled: A challenging case.

Authors:  Anderson Rodrigues Brandão de Paiva; Carlos Rory Pucci Filho; Alan Monteiro Porto; Fabrício Stewan Feltrin; Fernando Kok; Carlos Henrique Ferreira Camargo
Journal:  Neurol Clin Pract       Date:  2018-04

6.  Bladder and Bowel Dysfunction Is Common in Both Men and Women with Mutation of the ABCD1 Gene for X-Linked Adrenoleukodystrophy.

Authors:  Johann Hofereiter; Matthew D Smith; Jai Seth; Katarina Ivana Tudor; Zoe Fox; Anton Emmanuel; Elaine Murphy; Robin H Lachmann; Jalesh Panicker
Journal:  JIMD Rep       Date:  2015-03-13

7.  Metabolic rerouting via SCD1 induction impacts X-linked adrenoleukodystrophy.

Authors:  Quentin Raas; Malu-Clair van de Beek; Sonja Forss-Petter; Inge Me Dijkstra; Abigail Deschiffart; Briana C Freshner; Tamara J Stevenson; Yorrick Rj Jaspers; Liselotte Nagtzaam; Ronald Ja Wanders; Michel van Weeghel; Joo-Yeon Engelen-Lee; Marc Engelen; Florian Eichler; Johannes Berger; Joshua L Bonkowsky; Stephan Kemp
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

8.  Hematopoietic cell transplantation does not prevent myelopathy in X-linked adrenoleukodystrophy: a retrospective study.

Authors:  Björn M van Geel; Bwee Tien Poll-The; Aad Verrips; Jaap-Jan Boelens; Stephan Kemp; Marc Engelen
Journal:  J Inherit Metab Dis       Date:  2014-12-09       Impact factor: 4.982

9.  Adrenoleukodystrophy siblings with a novel ABCD1 missense variant presenting with phenotypic differences: a case report and literature review.

Authors:  Yuka Shibata; Masaaki Matsushima; Takashi Matsukawa; Hiroyuki Ishiura; Shoji Tsuji; Ichiro Yabe
Journal:  J Hum Genet       Date:  2020-10-30       Impact factor: 3.172

10.  Intrathecal Adeno-Associated Viral Vector-Mediated Gene Delivery for Adrenomyeloneuropathy.

Authors:  Yi Gong; Anna Berenson; Fiza Laheji; Guangping Gao; Dan Wang; Carrie Ng; Adrienn Volak; Rene Kok; Vasileios Kreouzis; Inge M Dijkstra; Stephan Kemp; Casey A Maguire; Florian Eichler
Journal:  Hum Gene Ther       Date:  2018-12-18       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.